Q2 net loss narrows to $1.9M; Plinabulin shows 23% ORR in ICI-refractory cancers

BeyondSpring Inc.

2025-Q2 EPS reported -$0.19

Net loss from continuing operations $1.9M for Q2 2025 vs $2.7M in Q2 2024; cash $9.5M as of Jun 30, 2025 vs $2.9M Dec 2024.
R&D expenses $1.0M; G&A $0.9M, down from $1.8M on lower headcount and professional costs.
Plinabulin combo in PD-1/L1 progressed NSCLC showed median PFS 6.8 mo, ORR 18.2%, DCR 77%, OS 78% at 15 mo.
SEED Therapeutics' RBM39 degrader ST-01156 cleared FDA IND; Dr. Bill Desmarais appointed CFO and CBO.
Discontinued operations loss $2.8M vs $1.4M YoY, reflecting SEED reporting change.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.